熱門資訊> 正文

BeOne Pharmaceuticals因肝癌资产获得孤儿药地位

2026-03-24 00:30

The US FDA has granted orphan drug status to BeOne Medicine's (ONC) BGB-B2033 for hepatocellular carcinoma, the most common type of liver cancer.
BGB-B2033 is an IgG-based bispecific antibody targeting GPC3 and 4-1BB in phase 1.
BeOne says that BGB-B2033's anti-tumor activity can potentially be enhanced with the company's Tevimbra (tislelizumab), an IgG4 anti-PD-1 monoclonal antibody.

More on BeOne Medicines

Tracking Baker Brothers Portfolio - Q4 2025 Update
BeOne Medicines: Guidance Weighs But Multiple Catalysts In 2026
BeOne Medicines AG (ONC) Q4 2025 Earnings Call Transcript
Most oversold healthcare stocks above $10B on Wall Street amid Middle East disruptions
BeiGene Q4 2025 Earnings Preview

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。